Nursing and Health Professions
Chronic Myeloid Leukemia
100%
Imatinib
77%
Patient
73%
Mortality
72%
Cohort Analysis
69%
Opiate
66%
Psoriasis
46%
Confidence Interval
42%
National Health Insurance
40%
Incidence
38%
Data Base
37%
Diseases
35%
Hazard Ratio
33%
Psoriatic Arthritis
33%
Tramadol
33%
Prevalence
33%
Cross-Sectional Study
33%
Clinical Outcome
33%
Quality of Life Measure
33%
Outpatient
33%
Control
33%
Primary Medical Care
33%
Infection
33%
Dose
21%
Treatment Outcome
18%
Drug Therapy
18%
Prescription
18%
Long Term Survival
16%
Malignant Neoplasm
14%
Time
13%
Mortality Rate
12%
Treatment Response
11%
Morphine
11%
Duragesic
11%
Cancer Pain
11%
Scoring System
11%
Socioeconomic Status
10%
Population
10%
Odds Ratio
9%
Proportional Hazards Model
8%
High Risk Population
8%
Death
8%
Diagnosis
6%
All Cause Mortality
6%
Person
6%
Logistic Regression Analysis
6%
Survival Rate
6%
Clinical Practice
5%
Survival Time
5%
Overall Survival
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Death
80%
Imatinib
77%
Mortality
72%
Opiate
66%
Diseases
42%
Gabapentinoid
38%
Cohort Study
36%
Psychotropic Agent
36%
Tramadol
33%
Drug Utilization
33%
Case-Control Study
33%
Psoriasis
33%
Infection
33%
Defined Daily Dose
19%
Long Term Survival
16%
Morphine
13%
Retrospective Study
8%
Incidence
7%
Prevalence
7%
Survival Rate
6%
Mortality Rate
6%
Overall Survival
5%
Survival Time
5%
Event Free Survival
5%
Side Effect
5%
Medicine and Dentistry
Mortality
66%
Patient
49%
Tramadol
33%
Gabapentinoid
33%
Ecological Study
33%
Chronic Myelogenous Leukemia
33%
Primary Health Care
33%
Drug
33%
Chemotherapeutic Agent
33%
Health
33%
Cohort Analysis
33%
Inpatient
33%
Psoriasis
33%
Infection
33%
Hazard Ratio
23%
Therapeutic Procedure
19%
Socioeconomic Status
16%
Long Term Survival
13%
Death
11%
Imatinib
11%
General Medicine
11%
Scoring System
11%
High Risk Population
8%
Diseases
7%
Incidence
7%
Prevalence
7%
Demography
5%
Population and Population Related Phenomena
5%
Overall Survival
5%
Event Free Survival
5%
Survival Time
5%
National Health Service
5%
